This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The three treatments under examination were PEG (subcutaneous injections at a dosage of 180μg every week for 48 weeks), interferon alpha (six million international units three times a week for 24 weeks) and lamivudine (100mg per day from 48 weeks to five years for HBeAg-positive chronic hepatitis B and 100 mg per day up to 5 years in HBeAgnegative chronic hepatitis B).
Location/setting
Lithuania/secondary care.
Methods

Analytical approach:
The analytic framework was based on a Markov model that simulated clinical and economic outcomes in a hypothetical cohort of 40-year-old patients with chronic hepatitis B. A lifetime horizon was considered. The authors stated that the analysis adopted the perspective of the National Health Insurance Fund.
Effectiveness data:
It appeared that clinical inputs for the model were taken from studies that might have been known to the authors and identified selectively. Rates of treatment response were key clinical inputs of the model. These were taken from clinical trials but it was unclear whether there was direct or indirect comparison. Other data for transition probabilities were obtained from observational studies that were not described. Some assumptions were made.
Monetary benefit and utility valuations:
Utility valuations associated with health states were taken from published sources (details not given).
Measure of benefit:
Life-years and quality-adjusted life-years (QALYs) were used as summary benefit measures and were discounted at an annual rate of 5%. Patients with complete response were reported.
Cost data:
NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination
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The economic analysis included costs of drugs (acquisition and administration) and all medical costs (in-patient treatment, outpatient consultations and examinations) associated with the health states of the model (long-term virologic response, chronic hepatitis B, cirrhosis, hepatocellular carcinoma and liver transplantation). Drug dosages were estimated according to official guidelines. Drug costs were based on producer's price for Lithuania and national drug price calculation methodology for compensated drugs. Costs for other medical services were taken from official price lists and reimbursement rates. Costs were in Lithuanian currency (Lt) and some were also reported in Euros (€). A 5% annual discount rate was applied.
Analysis of uncertainty:
One-way sensitivity analyses were carried out by varying efficacy rates within confidence intervals (CI) reported in published clinical trials.
Results
Total The study results were reported extensively. Incremental cost-effectiveness and cost-utility ratios were calculated appropriately to synthesise costs and benefits of the alternative strategies. The issue of uncertainty was partly investigated as sensitivity analyses focused exclusively on variations in treatment efficacy rates using published ranges of values. The authors stated that PEG was cost-effective assuming a threshold between $50,000 and $100,000 but this might not have been a relevant threshold for a middle-income country. The authors acknowledged some limitations of their analysis mostly related to sources of clinical data and the need for assumptions. Study results were specific to the Lithuanian setting and appeared difficult to translate to other settings.
Concluding remarks:
The analysis used a conventional cost-effectiveness framework in a hypothetical cohort of patients. Information on key data sources was limited. Caution is required in interpreting the authors' conclusions. 
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